This is the case of SF3B1 mutations, as a part of the 2016 World Health Organization diagnostic criteria of MDS-RS and TP53 mutations which identify a distinct disease entity of poor prognosis. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.